Needham Maintains Buy on Harmony Biosciences, Raises Price Target to $65

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.

Needham analyst Ami Fadia maintains Harmony Biosciences (NASDAQ:HRMY) with a Buy and raises the price target from $60 to $65.

Total
0
Shares
Related Posts